A patient died while taking Sarepta Therapeutics' Elevidys drug, leading European regulators to halt some studies on it. The patient's death was due to acute liver failure, a possible side effect of the treatment. Sarepta's stocks dropped after the announcement, declining by 6% on Friday morning.

In response to the patient's death, European regulators paused some testing of Elevidys, prompting Sarepta to halt recruitment and dosing in certain clinical trials. The company reported that the independent data monitoring committee will review the adverse event. This incident was the first reported death of someone taking the drug, despite acute liver injury being a known risk associated with Elevidys and similar gene therapies.

Three clinical trials were affected by the suspension, but ongoing monitoring and data collection for enrolled participants continue without a significant impact on the timeline. Sarepta's shares plummeted following the announcement and are currently at their lowest level in over seven years.